Colorimetric DNA/RNA sensor for point-of-care diagnostics
A naked-eye colorimetric detection platform that converts DNA/RNA targets into a visible color change, enabling instrument-free testing. Adapted from a patented hydrogen gas detection method, it offers high sensitivity and single-base mismatch capability for rapid, low-cost point-of-care diagnostics.
Overview
This solution is a colorimetric sensor designed for rapid, instrument-free detection of DNA and RNA markers at the point of care. It is built on a patented method originally developed for hydrogen gas detection, in which the target analyte triggers a sharp color shift in a testing solution from blue to pink that is visible to the naked eye. The platform has been adapted so that nucleic acid targets can be detected without the need for laboratory instruments, making it well suited for field, clinical, agricultural, and resource-limited settings.
Technical specifications
- Detection principle: Target DNA or RNA triggers a cascade reaction that produces a visible color change in the test solution, readable by eye or smartphone camera.
- Sensitivity: Demonstrated to detect DNA targets with high sensitivity, including the ability to distinguish single-base mismatches.
- Targeted format: A self-contained kit consisting of a test paper, three reagents, and a color reference chart.
- Workflow: The user dips the test paper into a sample, then sequentially into Reagent #1, Reagent #2, and Reagent #3. The final color of Reagent #3 is compared against the chart, either visually or via a smartphone photograph.
- Customization: For each new target, the test paper and Reagent #1 are customized, while Reagents #2 and #3 remain universal across targets, simplifying kit production and inventory.
- Readout options: Naked-eye interpretation or smartphone-based image comparison for added objectivity and data capture.
Technology readiness level
The underlying colorimetric method has been validated in laboratory studies showing sensitive DNA detection and single-base mismatch discrimination. Ongoing and planned work focuses on two aims: first, establishing the detection method for DNA and RNA markers using synthetic targets to benchmark sensitivity and specificity; and second, optimizing the workflow for point-of-care deployment under sponsor-defined conditions, culminating in a portable kit format. The technology is currently at an early-to-mid development stage, ready for collaborative optimization and pilot validation toward a field-ready product.
About University of Cincinnati
The University of Cincinnati is a comprehensive public research university with an applied, urban-serving character and a significant clinical enterprise. Industry engages through one of the nation's largest cooperative education programs, placing students year-round with corporate R&D and operations teams and creating an on-ramp to sponsored research. An innovation district near campus hosts co-located corporate labs, startup space, and shared prototyping facilities, while the university's integration with a major hospital system enables clinical studies and translation. Research is supported by competitive federal funding from agencies such as NIH and NSF, along with state and industry partnerships. A dedicated technology transfer office manages IP, licensing, corporate agreements, and startup formation, providing flexible models for collaboration.
delivered to your inbox.